Airway hyper-responsiveness (AHR) is a tenet of the persistent asthma phenotype along with reversible airway obstruction and type 2 (T2) inflammation. Indirect acting challenges such as mannitol are more closely related to the underlying T2 inflammatory process as compared with direct challenges. In this review article, we summarise the current literature and explore the future role of mannitol AHR in clinical remission with biologics.
Keywords: Airway hyper-responsiveness; Asthma; Biologic; Remission.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.